LONDON: Syncona Ltd, a leading healthcare company focused on founding, building and funding global leaders in life science, announced that the sale of its portfolio company Gyroscope Therapeutics Holdings plc to Novartis, a leading global medicines company, for total consideration of up to $1.5 billion (£1.1 billion1), has completed and the upfront cash payment of…